Islet transplantation is the only minimally invasive therapy for Type I diabetes that is able to achieve glycemic control without exogenous insulin. However, islet transplantation shows variable success rates, mainly due to the inconsistent quality of human islet preparations. For islet transplantation to become a FDA licensed biologic product, a well- established islet preparation process and product manufacturing consistency will need to be demonstrated. Federal regulations mandate that each biologic product lot be tested for potency before being released for clinical use. At present, there is no reliable potency test available for human pancreatic islets. We hypothesize that an appropriate islet potency test must be beta-cell specific and simultaneously assess key factors associated with islet physiology, including glucose- stimulated changes in mitochondrial potentials, calcium influx and dynamic insulin secretion. To test this hypothesis, an innovative islet perfusions system with functional, live microscopy was developed using microfluidic chip technology to enable simultaneous measurement of glucose-induced changes in mitochondrial potentials, calcium influx and dynamic insulin secretion. Preliminary results indicate that this system can adequately distinguish low potency from high potency human islet preparations. This project will focus on the following aims: (1) To further improve the resolution of the microfluidic system through modification of the chip design. Specifically, our proposal focuses on: a. improving temporal resolution by reducing the volume of the chamber within the microfluidic chip, b. improving flow dynamic control and increasing ease of use by adding a fluid mixer into the chip, c. establishing glucose ramps to evaluate insulin kinetics, d. integrating multiple perfusion chambers into the chip on a motorized platform to increase the sample size of human islets that can be evaluated and provide a better representation of the final islet product. e. developing a rapid insulin secretion measurement. (2) To validate the microfluidic system in a pre-clinical nude mouse model using human islet cell grafts and develop an """"""""Islet Potency Index """""""" predictive of post-transplant islet graft function. Briefly, multivariable regression modeling will determine which islet cell characteristics are significantly associated with in vivo outcome and these will be used to calculate the index. (3) To test the microfluidic system in setting of a clinical human islet transplant trial and investigate the validity of the Islet Potency Index to predict islet graft function. This proposal will test an innovative microfluidic system that provides detailed analysis of pancreatic beta-cell physiology. In the future, it is likely that further developments addressing an unlimited islet cell source and new immunoprotective strategies will make islet transplantation available to a broader proportion of the diabetic population. This microfluidic system could represent a reliable islet potency assay for current and future islet replacement therapies, as well as for the study of new diabetes therapies in general.

Public Health Relevance

An innovative microfluidic system will be optimized and standardized for human islet potency testing. If successful, the microfluidic-based assay could be used for islet product release testing, which represents a yet unmet regulatory requirement for FDA biologic licensure of islet transplants.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Instrumentation and Systems Development Study Section (ISD)
Program Officer
Appel, Michael C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Illinois at Chicago
Schools of Medicine
United States
Zip Code
Sui, Lina; Danzl, Nichole; Campbell, Sean R et al. (2018) ?-Cell Replacement in Mice Using Human Type 1 Diabetes Nuclear Transfer Embryonic Stem Cells. Diabetes 67:26-35
Doloff, Joshua C; Veiseh, Omid; Vegas, Arturo J et al. (2017) Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nat Mater 16:671-680
Vegas, Arturo J; Veiseh, Omid; Doloff, Joshua C et al. (2016) Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat Biotechnol 34:345-52
Nourmohammadzadeh, Mohammad; Xing, Yuan; Lee, Jin Wuk et al. (2016) A microfluidic array for real-time live-cell imaging of human and rodent pancreatic islets. Lab Chip 16:1466-72
Wang, Yong; Wang, Shusen; Harvat, Tricia et al. (2015) Diazoxide, a K(ATP) channel opener, prevents ischemia-reperfusion injury in rodent pancreatic islets. Cell Transplant 24:25-36
Shang, Jin; Li, Jing; Keller, Mark P et al. (2015) Induction of miR-132 and miR-212 Expression by Glucagon-Like Peptide 1 (GLP-1) in Rodent and Human Pancreatic ?-Cells. Mol Endocrinol 29:1243-53
Veiseh, Omid; Doloff, Joshua C; Ma, Minglin et al. (2015) Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat Mater 14:643-51
Li, Liang-cheng; Wang, Yong; Carr, Ryan et al. (2014) IG20/MADD plays a critical role in glucose-induced insulin secretion. Diabetes 63:1612-23
Lo, Joe Fu-Jiou; Wang, Yong; Li, Zidong et al. (2013) Quantitative and temporal control of oxygen microenvironment at the single islet level. J Vis Exp :e50616
Wang, Yong; Qi, Meirigeng; McGarrigle, James J et al. (2013) Use of glucagon-like peptide-1 agonists to improve islet graft performance. Curr Diab Rep 13:723-32

Showing the most recent 10 out of 17 publications